Nasus Pharma (NSRX) CFO exit ushers in long-time insider as interim
Rhea-AI Filing Summary
Nasus Pharma Ltd (NSRX), a clinical-stage biopharmaceutical company focused on innovative intranasal therapies, announced that its Chief Financial Officer, Eyal Rubin, has resigned, effective September 18, 2026. The company states that his resignation is not related to any disagreement regarding operations, policies, or practices. Rubin will remain through the effective date to support a seamless transition. Oren Elmaliach, currently Director of Finance and with Nasus since its inception, has been appointed Interim Chief Financial Officer. Elmaliach is a certified public accountant with over 15 years of financial experience, including work with public and private life sciences companies and within the U.S. public markets and reporting environment. The 6-K (excluding parts of the press release) is incorporated by reference into Nasus Pharma’s Form S-8 registration statement.
Positive
- None.
Negative
- CFO resignation announced, with Chief Financial Officer Eyal Rubin leaving effective September 18, 2026, creating a key finance leadership transition.
Key Figures
CFO resignation effective date: September 18, 2026
Press release date: August 19, 2026
Financial experience of Interim CFO: more than 15 years
+2 more
5 metrics
CFO resignation effective date
September 18, 2026
Effective date of Chief Financial Officer Eyal Rubin’s resignation
Press release date
August 19, 2026
Date of press release announcing Nasus Pharma’s CFO transition
Financial experience of Interim CFO
more than 15 years
Oren Elmaliach’s financial experience, including life sciences and U.S. public markets
Form S-8 file number
333-296252
Registration Statement into which this Form 6-K is incorporated by reference
Commission File Number
001-42796
SEC Commission File Number for Nasus Pharma Ltd as a foreign private issuer
Key Terms
foreign private issuer, Form 20-F, intranasal powder technology platform, forward-looking statements, +1 more
5 terms
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Form 20-F regulatory
"whether the registrant files or will file annual reports under cover of Form 20-F"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
intranasal powder technology platform medical
"advancing innovative intranasal therapies through its proprietary intranasal powder technology platform"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Registration Statement on Form S-8 regulatory
"incorporated by reference into the Company’s Registration Statement on Form S-8"
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
FAQ
What leadership change did Nasus Pharma Ltd (NSRX) announce in this 6-K?
Nasus Pharma announced that Chief Financial Officer Eyal Rubin resigned, effective September 18, 2026. He will remain until then to support an orderly transition, while Director of Finance Oren Elmaliach has been appointed Interim Chief Financial Officer.
When does the CFO transition at Nasus Pharma (NSRX) become effective?
The CFO transition becomes effective on September 18, 2026, when Eyal Rubin’s resignation takes effect. Until that date, he will work with Nasus Pharma to help ensure a seamless and orderly transition of chief financial officer responsibilities.
Who is replacing the departing CFO at Nasus Pharma (NSRX)?
Oren Elmaliach, the Company’s Director of Finance, has been appointed Interim Chief Financial Officer. Elmaliach has been with Nasus since inception and brings over 15 years of financial experience, including extensive work with life sciences companies and U.S. public markets.
How is this 6-K for Nasus Pharma (NSRX) used in its SEC filings?
This Form 6-K, excluding the second and third paragraphs of the attached press release, is incorporated by reference into Nasus Pharma’s Form S-8 registration statement (File No. 333-296252), becoming part of that registration statement as of its submission date.
What type of company is Nasus Pharma Ltd (NSRX) and what is its lead product?
Nasus Pharma is a biopharmaceutical company developing innovative intranasal therapies using a proprietary powder platform. Its lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis.
AI-generated analysis. How Rhea-AI works. Not financial advice.
